These guidelines update the 2008 UK guideline for the management of sexually acquired reactive arthritis. The guideline is aimed at those over the age of 16 years, presenting to healthcare professionals working in sexual health services. The recommendations are primarily aimed at services offering level 3 care in sexually transmitted infection management within the United Kingdom. However, the principles will apply to those presenting to level 1 and 2 services, and appropriate local referral pathways will need to be developed.
SchumacherHRJrMaggeSCherianPV, et al.Light and electron microscopic studies on the synovial membrane in Reiter’s syndrome. Immunocytochemical identification of chlamydial antigen in patients with early disease. Arthritis Rheum1988; 31: 937–946.
2.
Taylor-RobinsonDGilroyCBThomasBJ, et al.Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet1992; 340: 81–82.
3.
RahmanMUCheemaMASchumacherHR, et al.Molecular evidence for the presence of chlamydia in the synovium of patients with Reiter’s syndrome. Arthritis Rheum1992; 35: 521–529.
4.
BasSGriffaisRKvienTK, et al.Amplification of plasmid and chromosome chlamydia DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies. Arthritis Rheum1995; 38: 1005–1013.
5.
BraniganPJGérardHCHudsonAP, et al.Comparison of synovial tissue and synovial fluid as the source of nucleic acids for detection of Chlamydia trachomatis by polymerase chain reaction. Arthritis Rheum1996; 39: 1740–1746.
6.
LiFBulbulRSchumacherHRJr, et al.Molecular detection of bacterial DNA in venereal-associated arthritis. Arthritis Rheum1996; 39: 950–958.
7.
NikkariSPuolakkainenMYli-KerttulaU, et al.Ligase chain reaction in detection of chlamydia DNA in synovial fluid cells. Br J Rheumatol1997; 36: 763–765.
8.
VittecoqOSchaeverbekeTFavreS, et al.Molecular diagnosis of ureaplasma urealyticum in an immunocompetent patient with destructive reactive polyarthritis. Arthritis Rheum1997; 40: 2084–2089.
9.
TullyJGRoseDLBasemanJB, et al.Mycoplasma pneumoniae and mycoplasma genitalium mixture in synovial fluid isolate. J Clin Microbiol1995; 33: 1851–1855.
10.
GérardHCBraniganPJSchumacherHRJr, et al.Synovial chlamydia trachomatis in patients with reactive arthritis/Reiter’s syndrome are viable but show aberrant gene expression. J Rheumatol1998; 25: 734–742.
11.
RihlMKlosAKöhlerL, et al.Infection and musculoskeletal conditions: reactive arthritis. Best Pract Res Clin Rheumatol2006; 20: 1119–1137.
12.
GérardHCWhittum-HudsonJACarterJD, et al.The pathogenic role of Chlamydia in spondyloarthritis. Curr Opin Rheumatol2010; 22: 363–367.
13.
GerardHCStanichJAWhittum-HudsonJA, et al.Patients with Chlamydia-associated arthritis have ocular (trachoma), not genital, serovars of C. trachomatis in synovial tissue. Microb Pathog2010; 48: 62–68.
14.
PerryMEOWhiteJA. Three cases of reactive arthritis secondary to lymphogranuloma venereum. J Clin Rheumatol2015; 21(1): 33–34.
15.
MasonEWrayLFosterR, et al.Reactive arthritis at the Sydney sexual health centre 1992-2012: declining despite increasing chlamydia diagnoses. Int J STD AIDS2015; 27: 882–889.
16.
CsonkaGW. The course of Reiter’s syndrome. Br Med J1958; 1: 1088–1090.
17.
RosenthalLOlhagenBEkS. Aseptic arthritis after gonorrhoea. Ann Rheum Dis1980; 39: 141–146.
18.
LeirisaloMSkylvGKousaM, et al.Followup study on patients with Reiter’s disease and reactive arthritis, with special reference to HLA-B27. Arthritis Rheum1982; 25: 249–259.
19.
KousaM. Clinical observations on Reiter’s disease with special reference to the venereal and non-venereal aetiology. Acta Derm Venereol Suppl (Stockh)1978; 58(Suppl S1): 1–36.
20.
CsonkaGW. Workshop I. Features and prognosis of Reiter’s syndrome. Clinical aspects of Reiter’s syndrome. Ann Rheum Dis1979; 38(Suppl): 4–7.
21.
Taylor-RobinsonDKeatA. Observations on Chlamydia trachomatis and other microbes in reactive arthritis. Int J STD AIDS2015; 26(3): 139–144.
Taylor-RobinsonDGilroyCBHorowitzS, et al.Mycoplasma genitalium in the joints of two patients with arthritis. Eur J Clin Microbiol Infect Dis1994; 13(12): 1066–1069.
24.
SchaeverbekeTRenaudinHVernhesJP, et al.Ureaplasma urealyticum and reactive arthritis. Clin Rheumatol1995; 14: 252.
25.
HorowitzSHorowitzJTaylor-RobinsonD, et al.Ureaplasma urealyticum in Reiter’s syndrome. J Rheumatol1994; 21: 877–882.
26.
KennedySLMuriraJWenhamCY. A case of reactive arthritis secondary to sexually acquired Shigella flexneri. Oxf Med Case Rep2017; 2017: 210–211.
27.
ChenMDelpechVO’Sulliva’nB, et al.Shigella sonnei: another cause of sexually acquired reactive arthritis. Int J STD AIDS2002; 13(2): 135–136.
KeatA. Reiter’s syndrome and reactive arthritis in perspective. N Engl J Med1983; 309: 1606–1615.
30.
KeatACMainiRNPegrumGD, et al.The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis. Q J Med1979; 48: 323–342.
31.
Leirisalo-RepoMRepoHHochbergMC. Reactive arthritis: clinical features and treatment. In: SilmanAJSmolenJSWeinblattME, et al. (eds) Rheumatology. 5th ed. Philadelphia: Mosby Elsevier; 2011. Section 8: Infection-related rheumatic diseases, 110, pp. 1113–1120.
32.
KeatACMainiRNNkwaziGC, et al.Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. Br Med J1978; 1: 605–607.
33.
HamdulaySSGlynneSJKeatA. When is arthritis reactive?. Postgrad Med J2006; 82: 446–453.
34.
MartinDHPollockSKuoCC, et al.Chlamydia trachomatis infections in men with Reiter’s syndrome. Ann Intern Med1984; 100: 207–213.
SteinCMDavisP. Arthritis associated with HIV infection in Zimbabwe. J Rheumatol1996; 23: 506–511.
37.
ClarkMRSolingerAMHochbergMC. Human immunodeficiency virus infection is not associated with Reiter’s syndrome. Data from three large cohort studies. Rheum Dis Clin North Am1992; 18: 267–276.
38.
AdizieTMootsRJHodkinsonB, et al.Inflammatory arthritis in HIV positive patients: a practical guide. BMC Infect Dis2016; 16: 100.
39.
CsonkaGW. Long-term follow-up and prognosis of Reiter’s syndrome. Ann Rheum Dis1979; 38(Suppl): 24–28.
40.
KousaMSaikkuPRichmondS, et al.Frequent association of chlamydial infection with Reiter’s syndrome. Sex Transm Dis1978; 5: 57–61.
41.
FloresDMarquezJGarzaM, et al.Reactive arthritis: newer developments. Rheum Dis Clin North Am2003; 29: 37–59. vi.
42.
GoodAE. Reiter’s syndrome: long-term follow-up in relation to development of ankylosing spondylitis. Ann Rheum Dis1979; 38(Supp l): 39–45.
43.
PopertAJGillAJLairdSM. A prospective study of reiter’s syndrome. An interim report on the first 82 cases. Br J Vener Dis1964; 40: 160–165.
44.
HannuTNieminenMSSwanH, et al.Cardiac findings of reactive arthritis: an observational echocardiographic study. Rheumatol Int2002; 21: 169–172.
45.
KonttinenYTBergrothVNordströmD, et al.IgA nephropathy in reactive arthritis. J Rheumatol1987; 14: 1070–1071.
FrydénABengtssonAFobergU, et al.Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study. BMJ1990; 301: 1299–1302.
51.
BardinTEnelCCornelisF, et al.Antibiotic treatment of venereal disease and Reiter’s syndrome in a Greenland population. Arthritis Rheum1992; 35: 190–194.
52.
NordströmDLindyOLauhioA, et al.Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int1998; 17: 175–180.
53.
LauhioALeirisalo-RepoMLähdevirtaJ, et al.Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to chlamydia arthritis. Arthritis Rheum1991; 34: 6–14.
54.
SieperJFendlerCLaitkoS, et al.No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum1999; 42: 1386–1396.
55.
Yli-KerttulaTLuukkainenRYli-KerttulaU, et al.Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis2000; 59: 565–570.
56.
KvienTKGastonJSBardinT, et al.Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis2004; 63: 1113–1119.
57.
SmiejaMMacPhersonDWKeanW, et al.Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Ann Rheum Dis2001; 60: 1088–1094.
58.
WakefieldDMcCluskeyPVermaM, et al.Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis Rheum1999; 42: 1894–1897.
59.
WollenhauptJHammerMPottHG, et al.A double-blind, placebo-controlled comparison of 2 weeks versus 4 months treatment with doxycycline in chlamydia-induced reactive arthritis. Arthr Rheum1997; 40(Supp l): S143.
60.
PutschkyNPottHGKuipersJG, et al.Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. Ann Rheum Dis2006; 65: 1521–1524.
61.
Dreses-WerringloerUPadubrinIZeidlerH, et al.Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob Agents Chemother2001; 45: 3001–3008.
62.
CarterJDValerianoJVaseyFB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol2004; 31: 1973–1980.
63.
CarterJDEspinozaLRInmanRD, et al.Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum2010; 62: 1298–1307.
64.
Leirisalo-RepoPaimelaMLJulkunenHPeltomaaR, et al.A 3-month, randomised, placebo-controlled study with combination antimicrobial therapy in acute reactive arthritis. Arthritis Rheum2001; 44(Suppl): S91.
65.
Yli-KerttulaTLuukkainenRYli-KerttulaU, et al.Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis2003; 62: 880–884.
66.
LaasilaKLaasonenLLeirisalo-RepoM. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis2003; 62: 655–658.
67.
PottHGWittenborgAJunge-HülsingG. Long-term antibiotic treatment in reactive arthritis. Lancet1988; 1: 245–246.
68.
BarberCEKimJInmanRD, et al.Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis. J Rheumatol2013; 40: 916–928.
69.
AnandarajahARitchlinCT. Treatment update on spondyloarthropathy. Curr Opin Rheumatol2005; 17: 247–256.
70.
NICE guideline [NG65]. Spondyloarthritis in over 16s: diagnosis and management. Published February 2017. Available at: https://www.nice.org.uk/guidance/ng65
71.
CombeBLandeweRLukasC, et al.EULAR recommendations for the management of early arthritis: report of a task force of the European standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis2007; 66: 34–45.
72.
ToivanenAToivanenP. Epidemiologic, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Curr Opin Rheumatol1995; 7: 279–283.
73.
CuellarMLEspinozaLR. Management of spondyloarthropathies. Curr Opin Rheumatol1996; 8: 288–295.
74.
Leirisalo-RepoM. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am1998; 24: 737–751. viii.
75.
PatronoC. Non-steroidal anti-inflammatory drugs. In: HochbergMCSilmanAJSmolenJS, et al. (eds) Rheumatology. 5th ed. Philadelphia: Mosby Elsevier; 2011. Section 4: Principles of management, 50, pp. 485–493.
76.
JuvakoskiTLassusA. A double-blind cross-over evaluation of ketoprofen and indomethacin in Reiter’s disease. Scand J Rheumatol1982; 11: 106–108.
77.
DougadosMNguyenMCaporalR, et al.Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol1994; 23: 243–248.
78.
WieneckeTGøtzschePC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev2004; (1): CD003789.
79.
PalazziCOlivieriID’AmicoE, et al.Management of reactive arthritis. Expert Opin Pharmacother2004; 5: 61–70.
McGettiganPHenryD. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA2006; 296: 1633–1644.
84.
KearneyPMBaigentCGodwinJ, et al.Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ2006; 332: 1302–1308.
85.
RayWAVaras-LorenzoCChungCP, et al.Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes2009; 2: 155–163.
86.
BlythTHunterJAStirlingA. Pain relief in the rheumatoid knee after steroid injection. A single-blind comparison of hydrocortisone succinate, and triamcinolone acetonide or hexacetonide. Br J Rheumatol1994; 33: 461–463.
87.
CanosoJJNaredoEHochbergMC. Aspiration and injection of joints and periarticular tissues and intralesional therapy. In: SilmanAJSmolenJSWeinblattME, et al. (eds) Rheumatology. 5th ed. Philadelphia: Mosby Elsevier; 2011. Section 4: Principles of management, 66, pp. 617–628
88.
CalinA. Workshop III. Management of Reiter’s syndrome. Ann Rheum Dis1979; 38(Suppl): 96–97.
89.
GünaydinIPereiraPLDaikelerT, et al.Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol2000; 27: 424–428.
90.
ThiersBH. The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. J Am Acad Dermatol1997; 37: S69–S71.
91.
OwenETCohenML. Methotrexate in Reiter’s disease. Ann Rheum Dis1979; 38: 48–50.
92.
HomikJSuarez-AlmazorMESheaB, et al.Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev1998; 2(2): CD000952.
93.
CranneyAWelchVAdachiJ, et al.Calcitonin for preventing and treating corticosteroid-induced osteoporosis. Cochrane Database Syst Rev2000; 1: CD001983.
94.
HomikJCranneyASheaB, et al.Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev1999; (1): CD001347.
95.
DougadosMvam der LindenSLeirisalo-RepoM, et al.Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum1995; 38: 618–627.
96.
CleggDORedaDJWeismanMH, et al.Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome). A department of veterans affairs cooperative study. Arthritis Rheum1996; 39: 2021–2027.
97.
EgsmoseCHansenTMAndersenLS, et al.Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann Rheum Dis1997; 56: 32–36.
98.
CleggDORedaDJAbdellatifM. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veterans affairs cooperative study. Arthritis Rheum1999; 42: 2325–2329.
99.
BraunJZochlingJBaraliakosX, et al.Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis2006; 65: 1147–1153.
100.
LipskyPEvan der HeijdeDMSt ClairEW, et al.Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med2000; 343: 1594–1602.
101.
BathonJMMartinRWFleischmannRM, et al.A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med2000; 343: 1586–1593.
102.
GenoveseMCBathonJMMartinRW, et al.Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum2002; 46: 1443–1450.
103.
ReimoldAM. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci2003; 325: 75–92.
104.
KhanMA. Update on spondyloarthropathies. Ann Intern Med2002; 136: 896–907.
105.
BraunJBrandtJListingJ, et al.Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet2002; 359: 1187–1193.
106.
GormanJDSackKEDavisJCJr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med2002; 346: 1349–1356.
107.
BraunJSieperJ. Biological therapies in the spondyloarthritides-the current state. Rheumatology (Oxford)2004; 43: 1072–1084.
108.
van der HeijdeDKivitzASchiffMH, et al.Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum2006; 54: 2136–2146.
109.
KavanaughATutuncuZCatalan-SanchezT. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol2006; 18: 347–353.
110.
MeasePJGoffeBSMetzJ, et al.Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet2000; 356: 385–390.
111.
AntoniCKruegerGGde VlamK, et al.Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis2005; 64: 1150–1157.
112.
MeasePJGladmanDDRitchlinCT, et al.Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum2005; 52: 3279–3289.
113.
van der BoschFKruithofEBaetenD, et al.Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum2002; 46: 755–765.
114.
KruithofEDe RyckeLRothJ, et al.Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum2005; 52: 3898–3909.
115.
RosenbaumJTSmithJR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol2002; 20(Suppl 28): S143–S145.
116.
BraunJBaraliakosXListingJ, et al.Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum2005; 52: 2447–2451.
117.
TheodossiadisPGMarkomichelakisNNSfikakisPP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina (Philadelphia, Pa)2007; 27: 399–413.
118.
Levy-ClarkeGReedGNussenblattR. Is anti-tumor necrosis factor therapy effective in reducing uveitis flares in patients with spondyloarthropathies?Nat Rev Rheumatol2007; 3: 376–377.
119.
KeaneJGershonSWiseRP, et al.Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med2001; 345: 1098–1104.
120.
BaetenDKruithofEvan den BoschF, et al.Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?Ann Rheum Dis2003; 62: 829–834.
121.
MeyerAChatelusEWendlingD, et al.Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum2011; 63: 1274–1280.
122.
CarterJD. Treating reactive arthritis: insights for the clinician. Ther Adv Musculoskelet Dis2010; 2: 45–54.
123.
FlaggSDMeadorRHsiaE, et al.Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum2005; 53: 613–617.
124.
WechalekarMDRischmuellerMWhittleS, et al.Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab. J Clin Rheumatol2010; 16: 79–80.
125.
SchafranskiMD. Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection. Rheumatol Int2010; 30: 679–680.
126.
Kaipiainen-SeppänenONiinisaloHKorpilähdeT, et al.Treatment of reactive arthritis with infliximab. Scand J Rheumatol2003; 32: 122–124.
127.
MeadorRJHsiaECKitumnuaypongT, et al.Is etanercept (ENBREL) effective in the treatment of reactive and undifferentiated arthritis?Arthritis Rheum2001; 44(Suppl): S348.
128.
GaylisN. Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. J Rheumatol2003; 30: 407–411.
129.
CarterJDGerardHCHudsonAP. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis2008; 67: 1181–1183.
130.
van der HeijdeDCheng-Chung WeiJDougadosM, et al.Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet2018; 392(392): 2441–2451.
131.
MeasePJKavanaughAReimoldA, et al.Secukinumab provides Sustained Improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol2020; 2(1): 18–25.
132.
TaylorPC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford)2019; 58(Suppl 1): i17–i26.
133.
O’DuffyEKClunieGPLuiD, et al.Double blind glucocorticoid controlled trial of samarium-153 particulate hydroxyapatite radiation synovectomy for chronic knee synovitis. Ann Rheum Dis1999; 58: 554–558.
134.
PavlicaLNikolicDMagicZ, et al.Successful treatment of postvenereal reactive arthritis with synovectomy and 3 months’ azithromycin. J Clin Rheumatol2005; 11: 257–263.
135.
SmithGRobertsRHallC, et al.Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Br J Rheumatol1996; 35: 458–462.
136.
de WitWvan MourikIWiesenhaanPF. Prolonged maternal indomethacin therapy associated with oligohydramnios. Case reports. Br J Obstet Gynaecol1988; 95: 303–305.
FlintJPanchalSHurrellA, et al.BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford)2016; 55(9): 1693–1697.
139.
McGonagleDAydinSZGülA, et al.‘MHC-I-opathy’-unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol2015; 11: 731–740.
140.
SivaCTanjongGEZhouX, et al.Antibiotics for reactive arthritis. (Protocol). Cochrane Database Syst Rev2013; (9): CD006078. Art. No: CD006078.
